IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna 40138

4 studies enrolling now · 12 studies all time

What they study most

Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Advanced Systemic Mastocytosis (AdvSM), Aggressive Systemic Mastocytosis (ASM), Endometrial Cancer, High-risk Large B-cell Lymphoma (LBCL), Hypertension, Kidney Disease, Mast Cell Leukemia (MCL), Mild Thrombocytopenia, Mixed Lineage Acute Leukemia

Studies at this site

• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy — Recruiting now
• (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis — Recruiting now
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma — Recruiting now
• A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation — Recruiting now
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
• A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata — Running, not enrolling
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension — Completed
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma — Running, not enrolling
• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies — Stopped early
• Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome — Stopped early